A randomized phase 2 trial of erlotinib versus pemetrexed as second‐line therapy in the treatment of patients with advanced EGFR wild‐type and EGFR FISH‐positive lung adenocarcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|9|1379-1386

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.9, 2014-05, pp. : 1379-1386

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review

By  

Oncology Research and Treatment, Vol. 36, Iss. 9, 2013-08 ,pp. : 510-518

Karger

Access to resources Recommend Favorite

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report

By  

Case Reports in Oncology, Vol. 6, Iss. 1, 2013-03 ,pp. : 189-196

Karger

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2016-2024

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

By  

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite